AI Article Synopsis
- Idiopathic granulomatous hepatitis is a rare liver condition that causes symptoms like recurrent fevers, muscle pain, and enlarged liver/spleen without any infectious cause.
- Traditional treatment involves steroids, which often relieve symptoms quickly but can lead to recurrences when tapered off; alternative medications like azathioprine and methotrexate can be effective.
- This case study presents a patient who developed antibodies against common treatments infliximab and adalimumab, marking the first successful use of certolizumab pegol for managing this condition, demonstrating its effectiveness against idiopathic granulomatous hepatitis and related antibodies.
Article Abstract
Idiopathic granulomatous hepatitis is a rare condition characterized by hepatic granulomas with constitutional symptoms such as recurrent fevers, myalgias, and hepatosplenomegaly in the absence of infection or inflammatory disorder. Typical treatment and course of this disease consist of a course of steroids with rapid symptom resolution. However, symptoms may recur when steroids are tapered. In these circumstances, azathioprine, methotrexate, infliximab, and adalimumab have demonstrated good response. In this case, we present a patient who developed antidrug antibodies to infliximab and adalimumab and was the first documented case of this disease to be treated with certolizumab pegol. Our case highlights the novel efficacy of certolizumab pegol for idiopathic granulomatous hepatitis and its role in treating idiopathic granulomatous hepatitis with antidrug antibodies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10977590 | PMC |
| http://dx.doi.org/10.14309/crj.0000000000001310 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Although granulomatous interstitial nephritis (GIN) is a rare histological finding in kidney transplants, the joint occurrence of GIN and focal segmental glomerulosclerosis (FSGS) has not, to our knowledge, been reported in the literature. We report a case of GIN and de novo FSGS in kidney transplant recipients leading to allograft failure. A 69-year-old male with a history of end-stage renal disease (ESRD) of unknown etiology, as well as liver failure from hepatitis B and C co-infection, initially had a living unrelated kidney transplant (LURT) in 2007 and subsequently received both liver and kidney transplants (SLKTs) in 2017.
View Article and Find Full Text PDFBackground And Aims: Sarcoidosis is a multisystem disorder characterized by nonnecrotizing granulomas. Studies suggest 20%-70% of patients with sarcoidosis have abnormal liver chemistries or abdominal imaging. Hepatic sarcoidosis may be complicated by portal hypertension (portal HTN) with or without cirrhosis.
View Article and Find Full Text PDFInvolvement of Species in Spotty Liver Disease-like Lesions in Broiler Chickens Detected at Meat Inspections in Miyazaki Prefecture, Japan.
Microorganisms
November 2024
Center for Animal Disease Control, University of Miyazaki, Miyazaki 889-2192, Japan.
Spotty liver disease (SLD) affects free-range laying hens, leading to mortality and reduced egg production. species, including , have been associated with SLD cases worldwide. However, the cause of SLD-like lesions found in broilers in Japan still remains unclear.
View Article and Find Full Text PDFComputed Tomographic Findings in Dogs with Hepatic Bacterial Parenchymal Infection and Abscessation.
Animals (Basel)
November 2024
Southern Counties Veterinary Specialists, Independent Vetcare (IVC) Evidensia, Forest Corner Farm, Hangersley, Ringwood BH24 3JW, UK.
Bacterial liver parenchymal infections in dogs are rarely documented, and their imaging characteristics are scarce in the veterinary literature, especially in Computed Tomography (CT). This retrospective multicentric study aimed to describe the CT characteristics of parenchymal bacterial liver infection and abscessation in dogs and compare them with the human literature. Twenty dogs met the inclusion criteria.
View Article and Find Full Text PDFFrequency and Consequences of Immune Checkpoint Inhibitor-Associated Inflammatory Changes in Different Organs: An Autopsy Study Over 13 -Years.
Mod Pathol
December 2024
Department of Pathology and Molecular Pathology, University Hospital of Zurich, Zurich, Switzerland; University of Zurich, Zurich, Switzerland.
Although immune checkpoint inhibitors (ICIs) have revolutionized modern oncology, they are also associated with immune-related adverse events (irAEs). Previous histopathologic descriptions of organ-related inflammatory changes do not consider systemic effects of ICIs, because of the absence of comprehensive autopsy studies. We performed a retrospective study on 42 whole-body autopsies of patients treated with ICIs from January 2011 to March 2024 to determine the frequency, organ distribution, and morphology of ICI-associated inflammatory changes as well as their clinical relevance.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!